81. Managing Elevated Lipid Levels --- HealthandAge The approach to treatment. Before deciding on a treatment plan, the physician should exclude the possibility of secondary hyperlipidemia. http://www.healthandage.com/PHome/gid2=1549

June 2, 2004 Home Health Centers HealthandAge Network News ... Primer on Aging Choose Font Size Normal Large Extra Large Managing Elevated Lipid Levels Managing Elevated Lipid Levels Summarized by Robert W. Griffith, MD October 5, 2001 (Reviewed: October 15, 2003) This article is based on USA recommendations. Consequently, the units employed for lipid levels are mg/dL. For readers from those countries more familiar with the mmol/L units, it's possible to convert mg/dL to mmol/L by multiplying by 0.02586. Alternately, to convert mmol/L to mg/dL, divide by 0.02586. For triglycerides, the corresponding conversion factor is 0.01129. Introduction In May 2001 the US National Heart, Lung, and Blood Institute issued new guidelines for managing high cholesterol levels. The vigorous approach that has been proposed almost triples the number of adults who should be receiving lipid-lowering drugs. Here is a summary of the new guidelines, slightly simplified. The first step is to determine the subject's likely risk of having coronary heart disease (CHD), followed by treatment dependent on the actual lipid profile. Determine the risk level All adults should have a fasting lipoprotein profile (total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride) done every 5 years. The cholesterol levels are now classified as follows, based on data from studies that assess the risk of coronary events:

82. Linkage Of Familial Combined Hyperlipidemia To Chromosome 1q21-q23 National Public Health Institute of Finland Department of Human Molecular genetics. Linkage of familial combined hyperlipidemia to chromosome 1q21q23. http://www.ktl.fi/molbio/wwwpub/fchl/

National Public Health Institute of Finland Department of Human Molecular genetics Linkage of familial combined hyperlipidemia to chromosome 1q21-q23 Päivi Pajukanta , Ilpo Nuotio , Joseph D. Terwilliger , Kimmo V.K. Porkka , Kati Ylitalo , Jussi Pihlajamäki , Aki J. Suomalainen , Ann-Christine Syvänen , Terho Lehtimäki , Jorma S.A. Viikari , Markku Laakso , Marja-Riitta Taskinen , Christian Ehnholm , Leena Peltonen Department of Human Molecular Genetics, National Public Health Institute and Institute of Biomedicine, University of Helsinki, Finland Department of Medicine, University of Turku, Turku, Finland Columbia University, Department of Psychiatry and Columbia Genome Center, New York, USA Department of Biochemistry, National Public Health Institute, Helsinki, Finland Department of Medicine, University of Helsinki, Helsinki, Finland Department of Medicine, University of Kuopio, Kuopio, Finland Tampere University Hospital, University of Tampere, Tampere, Finland Nature Genetics More than half of patients with angiographically confirmed premature coronary heart disease (CHD) have a familial lipoprotein disorder Familial combined hyperlipidemia (FCHL) represents the most common genetic dyslipidemia with a prevalence of 1.0-2.0% and it is estimated to cause 10-20% of premature CHD. FCHL is characterized by elevation of cholesterol, triglycerides, or both. Attempts to characterize genes predisposing to FCHL have been hampered by equivocal phenotype definition, unknown mode of inheritance, and genetic heterogeneity. To minimize genetic heterogeneity, we chose 31 extended FCHL families which fulfilled strictly defined criteria for the phenotype status from the isolated Finnish population. Linkage analyses were performed with markers in ten chromosomal regions harboring lipid metabolism candidate genes. One marker

83. Hyperlipidemia Patient Compliance Market Analysis, Data & Figures hyperlipidemia medication noncompliance can have severe and costly clinical consequences, as well as measurable effects in terms of direct and indirect costs. http://www.the-infoshop.com/press/ww12400_en.shtml

Home Contact about The Infoshop Catalog ... Devices / Components Press Release Hyperlipidemia medication noncompliance can have severe and costly clinical consequences, as well as measurable effects in terms of direct and indirect costs. Also, underutilization of cholesterol lowering medications result in significant product revenue loss for pharmaceutical manufacturers. More importantly, lowering blood cholesterol levels can reduce the short-term risk for heart attack by 40%. The rate of compliance with hyperlipidemia treatments is low, causing an estimated 125,000 deaths per year. This Hyperlipidemia Patient Compliance report provides important insights into specific treatment compliance issues underlying hyperlipidemia, a lipid disorder also known as hypercholesterolemia or "high cholesterol." Despite the availability of numerous pharmaceuticals for the treatment of hyperlipidemia, significant obstacles to patients' compliance with these therapies, as well as dietary and exercise regimens, remain. The preventative, rather than curative nature of hyperlipidemia treatment is one such challenge. Numerous additional factors result in differing rates of compliance among patients. Patients report reasons for delay and/or omitted drug doses, as well as not following dietary and exercise regimens. Hyperlipidemia Patient Compliance is a newly released report from EP Publications, a service of WWMR, providing compliance rates, factors influencing compliance, strategies for improving compliance, and the resulting implications for the pharmaceutical industry. Key findings from patient interviews - including direct quotes, critical desires of patients in terms of compliance, reasons for non-compliance - are also included in the report.

84. [Report] Hyperlipidemia Patient Compliance - Economic And Clinical Implications This publication provides insight into key hyperlipidemia treatment compliance issues, including compliance rates, factors influencing compliance, industry http://www.the-infoshop.com/study/ww12400_hyperlipidemia.html

Home Contact about The Infoshop Catalog ... Devices / Components [Report] Hyperlipidemia Patient Compliance - Economic and Clinical Implications for the Pharmaceutical Industry Pub Time: 2003/02 Compliance Rates, Influential Factors, Industry Implications, and Strategies for Increasing Compliance This publication provides insight into key hyperlipidemia treatment compliance issues, including compliance rates, factors influencing compliance, industry implications, and strategies for improving compliance. It offers pharmaceutical marketing teams a better understanding of how patients feel about complying with current treatment options, and what they desire in the treatment of hyperlipidemia. Factors related to treatment regimens, patient demographics, disease characteristics, economics, and the patient-provider relationship that influence compliance are also revealed. Refine Forecasts by Incorporating Noncompliance Rates Predict product uptake more accurately using specific rate estimates of hyperlipidemia therapy compliance. Use disease- and drug-specific rates to develop more precise forecasts of product utilization by target sub-populations.

85. Hyperlipidemia Medical Nutrition Therapy Protocol CD-ROM hyperlipidemia Medical Nutrition Therapy Protocol CDROM. ADA now offers members and non-members the ADA MNT Evidence Based Guide for Practice on CD-ROM. http://www.eatright.org/Public/ContinuingEducation/96_8833.cfm

Login Shopping Cart Center for Professional Development Dietetic Practice Groups ... Calendar of Events (Enter a ZIP) Hyperlipidemia Medical Nutrition Therapy Protocol CD-ROM ADA now offers members and non-members the ADA MNT Evidence Based Guide for Practice on CD-ROM. The Hyperlipidemia MNT Protocol includes the latest recommendations Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III). A feature you will find in the ADA Medical Nutrition Therapy Evidence-Based Guides for Practice is the research, which is the foundation for the guides, organized in evidence worksheets showing the quality and strength of recommendations. For additional questions, send an email to: mntguides@eatright.org ISBN: 0-88091-300-2 Non-member Price: $30.00 Member Price: $20.00 Add to Cart View Cart Product Catalog

86. 33. Prospective Study Of Hyperlipidemia In ART-Naïve Subjects Taking Combivir/A Prospective Study of hyperlipidemia in ARTNaïve Subjects Taking Combivir/Abacavir (COM/ABC), COM/Nelfinavir (NFV), or Stavudine (d4T)/Lamivudine (3TC)/NFV http://63.126.3.84/2002/Abstract/13081.htm

Abstract E-mail Abstract Author Add To Itinerary Session Search Abstracts ... Program Session 7 Oral Abstract Session Opportunistic Infections and Complications of Antiretroviral Therapy Session Time: Monday, 10 am - 12:30 pm Room 6E Prospective Study of Hyperlipidemia in ART-Naïve Subjects Taking Combivir/Abacavir (COM/ABC), COM/Nelfinavir (NFV), or Stavudine (d4T)/Lamivudine (3TC)/NFV (ESS40002) P. Kumar* , A. Rodriguez-French , M. Thompson , K. Tashima , V. Williams , P. Wannamaker , and M. Shaefer Georgetown Univ. Med. Ctr., Washington, DC; San Fernando Hosp., Panama City, Panama; AIDS Res. Consortium, Atlanta, GA; The Miriam Hosp., Providence, RI; and GlaxoSmithKline, Res. Triangle Park, NC Background: Hyperlipidemia is a common side effect of HAART therapy. The effect that non-PI-containing regimens have on the development of hyperlipidemia and fat redistribution (FR) is not fully known. Our objectives were to evaluate changes in fasting metabolic parameters, clinical evaluations of FR, safety, and efficacy in subjects treated with COM/ABC vs COM/NFV vs d4T/3TC/NFV for 96 weeks.

87. Club C@reNet [club Hyperlipidemia] INDEX The summary for this Japanese page contains characters that cannot be correctly displayed in this language/character set. http://club.carenet.co.jp/hyperlipidemia/index.asp?SID=

88. The Body: Prospective Study Of Hyperlipidemia In ART-Naive Subjects Taking Combi Prospective Study of hyperlipidemia in ARTNaive Subjects Taking Combivir/Abacavir (COM/ABC), COM/Nelfinavir (NFV), or Stavudine (d4T)/Lamivudine (3TC)/NFV http://www.thebody.com/confs/retro2002/dejesus3.html

The Body Covers: The 9th Conference on Retroviruses and Opportunistic Infections Opportunistic Infections and Complications of Antiretroviral Therapy (Oral Abstract Session 7) Coverage provided by Edwin DeJesus, M.D. Abstract 33 Authored by P. Kumar , A. Rodriguez-French , M. Thompson , K. Tashima , V. Williams , P. Wannamaker , and M. Shaefer Georgetown Univ. Med. Ctr., Washington, DC; San Fernando Hosp., Panama City, Panama; AIDS Res. Consortium, Atlanta, GA; The Miriam Hosp., Providence, RI; and GlaxoSmithKline, Res. Triangle Park, NC) View the original abstract Metabolic complications and "lipodystrophy" have been the "price to pay" for the success of highly active antiretroviral therapy (HAART). One of the major metabolic problems our patients frequently encounter is hyperlipidemia. In multiple studies, protease inhibitors have been implicated as the major cause of elevations of cholesterol and triglycerides. (See " Risks for Cardiovascular Disease (CVD) Associated with Antiretroviral Therapy (ART) " ICCAC, 2001). Over the last few years several studies have also looked into possible ways to improve and possibly correct these lipid abnormalities. One of the most interesting approaches has been changing from a protease-inhibitor-based regimen to a reverse-transcriptase agent (nucleosides or non-nucleosides).

89. The Body: Prospective Study Of Hyperlipidemia In ART-Naive Subjects Taking Abaca Prospective Study of hyperlipidemia in ARTNaive Subjects Taking Abacavir/Combivir (ABC/COM), COM/nelfinavir (NFV), or Lamivudine (3TC)/Stavudine (d4T)/NFV http://www.thebody.com/confs/adrl2001/moyle7.html

The Body Covers: 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Coverage provided by Graeme Moyle, M.D. Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Abacavir/Combivir (ABC/COM), COM/nelfinavir (NFV), or Lamivudine (3TC)/Stavudine (d4T)/NFV (GSK Protocol ESS40002) Presenter: Princy Kumar Further Evidence of Metabolic Risks Lower with PI-Sparing Regimens Most of the research on metabolic disturbances, at least during the first few months of therapy, points to a role by protease inhibitors. Protease inhibitors appear to increase the release of fat from liver cells in vitro , at least in the presence of oleic acid (mimicking the intake of a fatty meal). In cultures of adipocytes, combining ritonavir with either AZT or d4T causes more release of fat from these fat cells than with RTV, AZT or d4T alone. Ritonavir, but not indinavir, leads to rises in cholesterol and triglycerides in healthy volunteers within a matter of weeks of starting therapy. Clinical studies suggest lopinavir/ritonavir is associated with more cholesterol and triglyceride rises than nelfinavir (in Abbott's M98-863 study), while the new protease inhibitor, atazanavir, has few, or perhaps no, effects upon lipids relative to nelfinavir (see ECCAT 2001 report ). Previous studies with protease inhibitor-sparing regimens have suggested that they have more favorable (especially nevirapine in the Atlantic and Combine studies) or less unfavorable effects on lipids than protease inhibitor-based therapy. It has not yet been established whether or not rises in lipids shortly after the initiation of therapy are a harbinger of future lipodystrophy.

90. Medical Encyclopedia expectations, factor, factors, familial, fat, fatty, greater, groups, hdl, health, heart, high, history, hyperlipidemia, hyperlipoproteinemia, incidence, intake http://www.medstarhealth.org/body.cfm?id=124&action=display&articlenum=403

91. Entrez PubMed Clinical assessment on treatment of hyperlipidemia with pushen capsule Article in Chinese Liu ZL, Wu SX, Gao GD. Guang anmen http://www.biomedcentral.com/pubmed/15074091

Entrez PubMed Nucleotide Protein ... Books Search PubMed Protein Nucleotide Structure Genome Books CancerChromosomes 3D Domains Domains Gene GEO GEO DataSets HomoloGene Journals MeSH NCBI Web Site OMIM PMC PopSet SNP Taxonomy UniGene UniSTS for Limits Preview/Index History Clipboard ... Text Version Entrez PubMed Overview FAQ Tutorial New/Noteworthy ... E-Utilities PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher ... Cubby Related Resources Order Documents NLM Gateway TOXNET Consumer Health ... PubMed Central Summary Brief Abstract Citation ASN.1 MEDLINE XML UI List LinkOut Related Articles Cited in Books CancerChrom Links Domain Links 3D Domain Links GEO DataSet Links Gene Links Genome Links GEO Links HomoloGene Links Nucleotide Links OMIM Links PMC Links Cited in PMC PopSet Links Protein Links SNP Links Structure Links UniSTS Links Show: Sort Author Journal Pub Date Text File Clipboard E-mail Order Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004 Mar;24(3):227-9. Related Articles, Links [Clinical assessment on treatment of hyperlipidemia with pushen capsule] [Article in Chinese] Liu ZL, Wu SX, Gao GD.

92. Ophthalmology Times - NAION May Herald Hyperlipidemia In Young NAION may herald hyperlipidemia in young patients. April 1, 2004. By Lynda Charters. Ophthalmology Times. PhiladelphiaNonarteritic http://www.ophthalmologytimes.com/ophthalmologytimes/article/articleDetail.jsp?i

93. Vitamin E As A Treatment Of Hyperlipidemia Home Vitamins Research Center Vitamin E Vitamin E as a Treatment of hyperlipidemia, Vitamin E as a Treatment of hyperlipidemia. http://www.vitamins-nutrition.org/vitamins-research/vitamin-e/vitamin-e-treatmen

Vitamins Research Center for the latest cutting edge information. Home Vitamins Research Center Vitamin E Vitamin E as a Treatment of Hyperlipidemia Clinical Study Title: Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Plain English Summary: This study looked at the use of vitamin E and C in combination for the treatment of hyperlipidemia in children. Hyperlipidemia is a risk factor for many chronic illnesses, such as atherosclerosis and coronary heart disease. A total of 15 children were given either a placebo or a daily combination of vitamin E and C, as well as put on a special diet. The use of the vitamin combination helped to improved brachial functioning. This suggests that a daily supplement including both vitamin C and E can help to improve heart function as well as help to reduce the risk of atherosclerosis and coronary heart disease. Authors Engler MM. Engler MB. Malloy MJ. Chiu EY. Schloetter MC. Paul SM. Stuehlinger M. Lin KY. Cooke JP. Morrow JD. Ridker PM. Rifai N. Miller E. Witztum JL. Mietus-Snyder M.

94. Hyperlipidemia On The Www hyperlipidemia on the www. USC Monogram. MEDLINEplus National Library of Medicine. hyperlipidemia. hyperlipidemia Symposium - Postgraduate Medicine (Dec 2000). http://medweb.usc.edu/pub/hyperlipidemia/www_hyperlipidemia.htm

Hyperlipidemia on the www MEDLINEplus - National Library of Medicine Lipid Disorders Lipid Disorders - acquired Familial combined hyperlipidemia Multiple lipoprotein-type hyperlipidemia (Freq = 1:100 heterozygous; 1:10,000 homozygous) Familial hypercholesterolemia (FH) Type II hyperlipoproteinemia; Hypercholesterolemic xanthomatosis; Low density lipoprotein receptor mutation; (Freq = 7:1,000; 10 million worldwide) Familial hypertriglyceridemia Elevated VLDL; (Freq = common) Familial dysbetalipoproteinemia Type III hyperlipoproteinemia; Deficient or defective apolipoprotein E (Freq = 1:10,000) Chylomicronemia syndrome Familial Lipoprotein Lipase Deficiency (1:million) Familial lipoprotein lipase deficiency (Freq = 1:million) Bassen-Kornzweig syndrome Abetalipoproteinemia; Acanthocytosis; Apolipoprotein B deficiency; (Freq = Rare, 70% males) Atherolsclerosis, Arteriosclerosis Atherosclerosis Hardening of the arteries Arteriosclerosis of the extremities Peripheral vascular disease; PVD; Arteriosclerosis obliterans Coronary Artery Disease (CAD) Coronary artery disease Stable angina Myocardial infarction Coronary artery disease (image) Coronary artery blockage (image) Stroke Stroke Cerebrovascular disease; CVA; Cerebrovascular accident

95. Hyperlipidemia (second Edition) Fast Facts hyperlipidemia (second edition). Familial (monogenic) hypercholesterolemia; Polygenic hypercholesterolemia and combined hyperlipidemia; http://www.healthpress.co.uk/new/basketdata/showbook.asp?bookid=67

96. NEJM -- Treatment Of And Screening For Hyperlipidemia Correspondence from The New England Journal of Medicine Treatment of and Screening for hyperlipidemia. Treatment of and Screening for hyperlipidemia. http://content.nejm.org/cgi/content/short/329/15/1124

HOME SEARCH CURRENT ISSUE PAST ISSUES ... HELP Please sign in for full text and personal services Previous Volume 329:1124-1128 October 7, 1993 Number 15 Next Treatment of and Screening for Hyperlipidemia Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings. Full Text Add to Personal Archive Add to Citation Manager E-mail When Cited ... PubMed Citation To the Editor: The study by Hunninghake et al. (April 29 issue), "The Efficacy of Intensive Dietary Therapy Alone or Combined with Lovastatin in Outpatients with Hypercholesterolemia," is very misleading. Despite the title of the article, a National Cholesterol Education Program Step 2 diet represents moderate dietary therapy, not "intensive" therapy. When dietary saturated fat and cholesterol are further restricted, patients tend to have much greater reductions in plasma low-density lipoprotein (LDL) cholesterol levels. The level of plasma LDL is regulated by the LDL receptor, a cell-surface glycoprotein that removes LDL from plasma by receptor-mediated endocytosis . Most Full Text of this Article References This article has been cited by other articles: Garrow, J, Watt, G, Doogan, D P, House, A, Freemantle, N, Millard, P H (1994). Conflict of interest: Sometimes consultancies cannot be disclosed.

97. BioSpace : CCIS : Search Results For Target = 'Hyperlipidemia' 2 Search Results for Target = hyperlipidemia . Protein knowledgebase Search SWISSPROT/TrEMBL for hyperlipidemia Genetic loci Search http://www.biospace.com/ccis/search.cfm?TargetID=199005

98. Welcome To PalmBeachPost! Acquired hyperlipoproteinemia; High blood cholesterol; High blood triglycerides; High cholesterol; High triglycerides; hyperlipidemia. Definition http://www.palmbeachpost.com/health/healthfd/shared/health/adam/ency/article/000

Jobs Autos Real Estate Classifieds ... Today's Post '); document.write(' HEALTH INDEX 5,000+ Area Doctors phone numbers Encyclopedia With symptoms and prevention tips Local Services Find Health services in your neighborhood Ask An Expert Get professional answers to medical questions Video Galleries Doctors explain medical terms and conditions Health Guides For women, children, Latest News Dozens of daily national PB Post Articles The most recent local health stories Today's Post Latest News Weekly Features Post Services GoPBI.com Search The Post: Illustrated Health Encyclopedia Important notice Ency. home Disease L Lipid Disorders - acquired Overview Symptoms Treatment Prevention Alternative names: Acquired hyperlipoproteinemia; High blood cholesterol; High blood triglycerides; High cholesterol; High triglycerides; Hyperlipidemia Definition: Aquired lipid disorders is a group of disorders characterized by an excess of fatty substances, such as cholesterol, triglycerides , and lipoproteins present in the blood. Causes and Risks Lipid disorders are caused by excess lipids or fatty substances in the blood, and are an important risk factor in developing

99. Gay.com Health Dealing With Side Effects Risks To Your Heart (hyperlipidemia) Many adults, as they get older, tend to experience an increase in their lipids (hyperlipidemia). http://www.gay.com/health/hiv/treatment/?sernum=2317

100. Penn State Faculty Research Expertise Database (FRED) , An excess of lipids in the blood. Related Terms, Dyslipidemia, Hyperlipemia.......Back. Faculty Research Expertise Database. hyperlipidemia. http://fred.hmc.psu.edu/ds/retrieve/fred/meshdescriptor/D006949

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 5     81-100 of 102    Back | 1  | 2  | 3  | 4  | 5  | 6  | Next 20